Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint

An update from Spero Therapeutics ( (SPRO) ) is now available.

On May 28, 2025, Spero Therapeutics and its partner GSK announced that their Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), met its primary endpoint and will stop early for efficacy. The trial demonstrated non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in hospitalized adult patients with cUTI, including pyelonephritis. This development positions tebipenem HBr to potentially become the first oral carbapenem antibiotic for US patients with cUTIs, addressing a significant healthcare need and potentially reducing hospitalizations and associated costs.

The most recent analyst rating on (SPRO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.

Spark’s Take on SPRO Stock

According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.

Spero Therapeutics is currently facing significant financial and operational challenges, as evidenced by declining revenues, negative profit margins, and operational inefficiencies. Technical analysis suggests ongoing bearish momentum, while valuation metrics highlight financial struggles due to a negative P/E ratio. The earnings call highlighted promising developments in their tebipenem HBr program, but these are offset by setbacks in other trials and increased financial losses. The overall score reflects these mixed but predominantly negative factors.

To see Spark’s full report on SPRO stock, click here.

More about Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need.

Average Trading Volume: 130,868

Technical Sentiment Signal: Sell

Current Market Cap: $38.13M

See more data about SPRO stock on TipRanks’ Stock Analysis page.